Curexo, a Korean company specializing in medical robots, said that it supplied 21 medical robots in the fourth quarter of 2022, bringing its total to 62 medical robots worldwide in 2022. 

The 62 medical robots include 39 CUVIS-joints surgical robots, 18 Morning Walks, and 5 InMotion Arms.

The company’s annual supply jumped from 18 in 2020 to 30 in 2021, and to 62 in 2022. 

CUVIS-joint is a surgical robot which performs total knee arthroplasty (TKA) and total hip arthroplasty (THA) in the field of orthopaedic surgery.

InMotion Arm is an upper extremity rehabilitation robot and CUVIS-spine provide precise movements as required for spinal surgery. 

Morning Walk is a gait rehabilitation robot developed for a fast recovery for patients with walking disabilities.

The rapid growth of robot supply will lead to sales growth and higher profitability even when the global economy is expected to suffer headwinds such as stronger dollar against the local currency and high interest rates in 2023, said a Curexo official.

Out of the 62 medical robots, 29 CUVIS-joint units were shipped to India's Merril Pharma and four to the U.S. Tri-State Industries (TSI).

"Our goal last year was to supply 50 units, but we are happy to have surpassed this goal," Curexo CEO Lee Jae-jun said, "This year, we aim to achieve more than 50 percent growth of sales in overseas markets based on our stable supply in the domestic market."

The company will also raise its status in the overseas medical robot market by expanding global sales through Merril Pharma, promoting CUVIS-joint's FDA licensing, stable entry into the U.S. market for CUVIS-spine and Morning Walk, and upgrading its medical robots and expanding indications, Lee added.